Multiple endocrine neoplasia type 2 other imaging findings
|
Multiple endocrine neoplasia type 2 Microchapters |
|
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Multiple endocrine neoplasia type 2 other imaging findings On the Web |
|
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 other imaging findings |
|
FDA on Multiple endocrine neoplasia type 2 other imaging findings |
|
CDC on Multiple endocrine neoplasia type 2 other imaging findings |
|
Multiple endocrine neoplasia type 2 other imaging findings in the news |
|
Blogs on Multiple endocrine neoplasia type 2 other imaging findings |
|
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
|
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [4]
Overview
Other imaging studies for multiple endocrine neoplasia type 2 include fluoro-di-glucose-PET, [18F]-fluorodopamine ([18F]DA) PET, and 99mTc-sestamibi scintigraphy.
Other Imaging Studies
Medullary Thyroid Carcinoma
- Radioactive iodine: Lesions do not concentrate radioactive iodine since the tumor does not arise from thyroid follicular cells.
- FDG-PET: Avid uptake is seen.[1]
- Tl-201: It has been shown to concentrate Thallium-201.[2]
- I-123 MIBG (metaiodobenzylguanidine): 30% of medullary thyroid cancer show uptake if the thyroid is blocked with Lugol's solution prior to the scan.
Pheochromocytoma
- [18F]-fluorodopamine ([18F]DA) PET is the best imaging modality for pheochromocytoma.
I-123 MIBG (metaiodobenzylguanidine)
- MIBG (123I- or 131I- metaiodobenzylguanidine) scintigraphy is another imaging modality for pheochromocytoma.
Octreotide (somatostatin) scans
- Over 70% of tumors express somatostatin receptors. Imaging is obtained 4 hours (+/- 24/48 hours) after an intravenous infusion. Unfortunately the kidney also has somatostatin receptors, as well as areas of inflammation, mammary glands, liver, spleen, bowel, gallbladder, thyroid gland and salivary glands.[3]
- Octreotide is usually labeled with either 111In-DTPA (Octreoscan) or (less commonly)123I-Tyr3-DTPA.
PET
Parathyroid Carcinoma
- 99mTc-sestamibi scintigraphy is a good imaging modality for hyperparathyroidism.
![Image courtesy of Dr Hani Al Salami[5]](/index.php/File:Nuclear_medicine.jpg)
![Image courtesy of Dr Roberto Schubert[6]](/index.php/File:Nuclear_medicine_02.jpg)
References
- ↑ "Radiopedia 2015 Medullary throid carcinoma [Dr Matt A. Morgan and Dr Yuranga Weerakkody]".
- ↑ Talpos GB, Jackson CE, Froelich JW, Kambouris AA, Block MA, Tashjian AH (1985). "Localization of residual medullary thyroid cancer by thallium/technetium scintigraphy". Surgery. 98 (6): 1189–96. PMID 2866591.
- ↑ Pacak, Karel (2007). Pheochromocytoma diagnosis, localization, and treatment. Malden, MA Oxford: Blackwell Pub. ISBN 1405149507.
- ↑ Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I; et al. (2002). "Pheochromocytomas: detection with 18F DOPA whole body PET--initial results." Radiology. 222 (2): 507–12. doi:10.1148/radiol.2222010622. PMID 11818620.
- ↑ Image courtesy of Dr Hani Al Salami. Radiopaedia (original file[1]).Creative Commons BY-SA-NC
- ↑ Image courtesy of Dr Roberto Schubert. Radiopaedia (original file[2]).Creative Commons BY-SA-NC